<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="187721">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00649909</url>
  </required_header>
  <id_info>
    <org_study_id>0020-08-HMO-CTIL</org_study_id>
    <nct_id>NCT00649909</nct_id>
  </id_info>
  <brief_title>Effect of Glucose Control on the Response to Aspirin in Type 2 Diabetic Patients</brief_title>
  <official_title>Effect of Glucose Control on the Response to Aspirin in Type 2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The efficacy of low dose aspirin appears to be substantially lower in diabetic patients,
      compared to patients without diabetes.

      We will perform an observational study where we follow up patients with uncontrolled type 2
      Diabetes Mellitus and low response to aspirin (Aspirin Resistance), during a period of 6
      months in the diabetic clinic. Our hypothesis is that glucose control will improve the
      response to aspirin in those patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">November 2010</completion_date>
  <primary_completion_date type="Anticipated">November 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The outcome measure is the laboratory Aspirin Resistance.</measure>
    <time_frame>3 and 6 months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the incidence of laboratory aspirin resistance in type 2 DM in stable out-patients in the diabetic clinic, and possibly related factors.</measure>
    <time_frame>On screening visit.</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Diabetes Mellitus, Type II</condition>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <description>Type 2 diabetic patients with reduced laboratory response to aspirin.(Aspirin Resistance)and with HbA1c &gt;8%.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Type 2 diabetic patients that take aspirin, from the diabetology clinic.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Type 2 DM.

          2. Patients that take aspirin.

          3. Antecubital forearm veins allowing technically good sampling for platelet studies.

          4. Reduced Laboratory response to aspirin.

          5. HbA1c &gt; 8 %

          6. The physician decides that there is an indication for glucose control.

        Exclusion Criteria:

          1. Acute ischemic stroke, acute coronary syndrome, (myocardial infarction or unstable
             angina pectoris), or revascularization by PCI or by-pass surgery within the last 6
             months.

          2. Acute kidney disease or chronic kidney disease with creatinine clearance &lt;30.

          3. Acute liver disease or chronic liver disease with severe liver impairment.

          4. Need for treatment with anticoagulants, clopidogrel, NSAID's, or thiazolidinediones.

          5. Thrombocytopenia (platelet count &lt;150 x 109/L)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Varon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hematology Department, Hadassah Medical Organization, Jerusalem, Israel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arik Tzukert, DMD</last_name>
    <phone>972 2 6776095</phone>
    <email>arik@hadassah.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hadas Lemberg, PhD</last_name>
    <phone>972 2 6777572</phone>
    <email>lhadas@hadassah.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hadassah Medical Organization</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Varon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <lastchanged_date>February 8, 2009</lastchanged_date>
  <firstreceived_date>March 27, 2008</firstreceived_date>
  <responsible_party>
    <name_title>Prof. David Varon, Hematology department, head of Coagulation Unit.</name_title>
    <organization>Hadassah Medical Organization.</organization>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Type II</keyword>
  <keyword>Aspirin</keyword>
  <keyword>Resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
